Targeted therapies for lung cancer patients with oncogenic driver molecular alterations
Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …
understanding of disease biology and the identification of oncogenic driver alterations has …
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …
short time frame at an affordable cost. While this technology has been widely implemented …
Strategies for the successful implementation of plasma-based NSCLC genoty** in clinical practice
Upfront tumour genoty** is now considered an essential step in guiding treatment
decision-making in the management of patients with advanced-stage non-small-cell lung …
decision-making in the management of patients with advanced-stage non-small-cell lung …
Biomarker-targeted therapies in non–small cell lung cancer: current status and perspectives
H Guo, J Zhang, C Qin, H Yan, T Liu, H Hu, S Tang… - Cells, 2022 - mdpi.com
Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)
Precision medicine was born with the development of new diagnostic techniques and
targeted drugs, yielding better outcomes in cancer care. With the evolution and increasing …
targeted drugs, yielding better outcomes in cancer care. With the evolution and increasing …
Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer
Detection of driver gene mutations is important in advanced NSCLC. The cobas EGFR
mutation test is a mutant allele-specific real-time PCR assay with limitation owing to its …
mutation test is a mutant allele-specific real-time PCR assay with limitation owing to its …
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: the KWAY Italian multicenter cost evaluation study
P Pisapia, F Pepe, A Baggi, M Barberis… - Critical Reviews in …, 2022 - Elsevier
Aims The KWAY project aims to investigate the economic sustainability of the up-front NGS
technologies adoption in the analysis of clinically relevant molecular alterations in NSCLC …
technologies adoption in the analysis of clinically relevant molecular alterations in NSCLC …
Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020
Importance Over the past 10 years, treatment of non–small cell lung cancer (NSCLC) has
been continually revolutionized. However, standard clinical trials may not reflect current …
been continually revolutionized. However, standard clinical trials may not reflect current …
Molecular subty** of small cell lung cancer
J Liang, X Guan, G Bao, Y Yao, X Zhong - Seminars in Cancer Biology, 2022 - Elsevier
Small cell lung cancer (SCLC), originating from lung neuroendocrine stem cells, is a
common pulmonary malignant tumor. SCLC, with poor prognoses, accounts for …
common pulmonary malignant tumor. SCLC, with poor prognoses, accounts for …
A BRAF new world
BRAF is a rare targetable mutation in non-small-cell lung cancer (NSCLC). Emerging
evidence underlines that, rather than a single point mutation, BRAF genes present with a …
evidence underlines that, rather than a single point mutation, BRAF genes present with a …